Infection-related acute care events contribute to increased morbidity and health care utilization among patients with glomerular disease (GD),1 and are a major concern for patients, caregivers, and health professionals.2 Novel therapeutic agents have reduced or eliminated glucocorticoids (GCs) from some treatment regimens for GD; however, GCs are still used frequently for remission induction or maintenance.3 Our previous analysis of infection risk in patients with GD found a 1.3 to 3 times higher risk of first infection in patients with GC exposure, but had limited clinical application owing to the absence of GC dosing information.